Excessive cardiac
fibrosis and
inflammation aberrantly contribute to the progressive pathogenesis of arrhythmogenic
cardiomyopathy (ACM). Whether
sodium-
glucose cotransporter-2 inhibitor (SGLT2i), as a new
hypoglycemic drug, benefits ACM remains unclear. Cardiomyocyte-specific Dsg2 exon-11 knockout and wild-type (WT) littermate mice were used as the animal model of ACM and controls, respectively. Mice were administered by gavage with either SGLT2i
dapagliflozin (DAPA, 1 mg/kg/day) or vehicle alone for 8 weeks. HL-1 cells were treated with DAPA to identify the molecular mechanism in vitro. All mice presented normal
glucose homeostasis. DAPA not only significantly ameliorated cardiac dysfunction, adverse remodeling, and ventricular dilation in ACM but also attenuated ACM-associated cardiac fibrofatty replacement, as demonstrated by the echocardiography and histopathological examination. The
protein expressions of HIF-2α and HIF-1α were decreased and increased respectively in cardiac tissue of ACM, which were compromised after DAPA treatment. Additionally, NF-κB P65 and IκB phosphorylation, as well as
fibrosis indicators (including TGF-β, α-SMA,
Collagen I, and
Collagen III) were increased in ACM. However, these trends were markedly suppressed by DAPA treatment. Consistent with these results in vitro, DAPA alleviated the IκB phosphorylation and NF-κB p65 transcriptional activity in DSG2-knockdown HL-1 cells. Interestingly, the elective HIF-2α inhibitor
PT2399 almost completely blunted the DAPA-mediated downregulation of indicators concerning cardiac
fibrosis and
inflammation. SGLT2i attenuated the ACM-associated cardiac dysfunction and adverse remodeling in a
glucose-independent manner by suppressing cardiac
fibrosis and
inflammation via reverting the HIF-2α signaling pathway, suggesting that SGLT2i is a novel and available
therapy for ACM.